ReviewCancers2019
RAD52 as a Potential Target for Synthetic Lethality-Based Anticancer Therapies.
Monika Toma et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
34 papers cite it
this papercites it
ReviewCancers2019
Monika Toma et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.